+++ ₿₿ +++ Handeln Sie mit Kryptowährungen mit Hebel - Jetzt mehr erfahren!** +++ ₿₿ +++-w-
22.07.2020 17:31:00

Why Aurinia Pharmaceuticals Is Up Today

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) are up by 10.4% as of 11:15 a.m. EDT on Wednesday, after the company announced that the U.S. Food and Drug Administration (FDA) accepted the filing of a New Drug Application (NDA) for Voclosporin. Voclosporin is a potential treatment for Lupus Nephritis, an inflammation of the kidneys that can lead to kidney failure. Lupus Nephritis is caused by systemic lupus erythematosus (SLE), which is an autoimmune disorder. Aurinia initially submitted its NDA for Voclosporin in late May. The FDA granted Voclosporin priority review, which reduces the process to six months, as opposed to the standard of 10 months. The health-industry regulator has assigned a target-action date of Jan. 22, 2021.Peter Greenleaf, CEO of Aurinia, said:Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu Aurinia Pharmaceuticals Incmehr Analysen

Eintrag hinzufügen

Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!

Aktien in diesem Artikel